Phase 2 N=16 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Relapsed Ewing Sarcoma · Refractory Ewing Sarcoma
Primary: Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0 — 1; 2; 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Evaluation of Cochlear Baha 5 SuperPower Sound Processor on the Baha Attract System
Single Sided Sensorineural Deafness · Mixed Hearing Loss, Unilateral
Primary: Audiometry; Free Field Thresholds. Pure Tone Average PTA4,Unaided vs Aided — -27.7 dB HL — p=<0.0001
Phase 1 N=45 SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.
Mild-Moderate Alzheimer's Disease · Healthy Elderly
Primary: Tolerability as Measured by Participant Withdrawal for an Adverse Event — 0; 0; 0; 0 Participants
Phase 3 N=248 Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1): Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 12 After the First Treatment — -1.25…
N/A N=150 Caries Prevention Effect of S-PRG Filler Incorporated in Denture Base Resins on Edentulous Elderly People
Dental Caries
Primary: Saliva Fluoride Concentration (Part Per Million,Ppm) — 0.05; 0.05; 0.09; 0.22 part per million,ppm — p=<0.05
Phase 1 N=6 Vaccination of High Risk Breast Cancer Patients
Stage IV Breast Cancer
Primary: Number of Participants With a Dose-limiting Toxicity (Defined as an Adverse Event of Grade 3 or Higher) — 0; 0 participants
Phase 1 N=20 A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib
Pulmonary Disease, Chronic Obstructive
Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of Nemiralisib in Plasma — 3199.0; 6272.7 Hours*picogram per…
Phase 2 N=42 A Study of LY2623091 in Male and Females With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change From Baseline to Day 21 in Proteinuria Based on 24-hours Pooled Urine — -98.9; -19.7; 119.4; 273.7 milligrams/24 hours (mg/24 h)
Phase 1 N=7 TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Breast Cancer · Breast Cancer - Female · Breast Cancer - Male
Primary: Recommended Phase II Dose (RP2D) — 400 dose in mg
Phase 3 N=251 IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
ESRD · Diabetes
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
N/A N=6 Focal Prostate Radio-Frequency Ablation
Prostate Cancer
Primary: Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA) — 3; 2; 1 Participants
N/A N=108 Presenting Summary Information From Cochrane Systematic Reviews to Physicians
Health Knowledge, Attitudes, Practice
Primary: Understanding of the Content of Summary Format — 8.0; 8.0; 8.0 units on a scale
N/A N=315 Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -
Osseous Paget's Disease
Primary: Percentage of Participants Who Had One or More Adverse Drug Reactions — 14.98 Percentage of Participants
N/A N=6,011 European Regulatory Science on Tobacco: Policy Implementation to Reduce Lung Diseases (EUREST-PLUS)
Tobacco Dependence
Primary: Number of Participants Who Think About the Harm of Smoking — 67; 272; 192; 194 Participants
Phase 1 N=119 Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 25354.4; 28896.8; 28684.8 h·μg/mL